CSF1R

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 9, 2022
NASDAQ, Large-cell lung carcinoma, EML4-ALK positive lung cancer, TRK, SRC, Cancer, Conference, GLOBE, Patient, ROS1, Therapy, ALK, MET, SAN, Pharmaceutical industry, CSF1R

SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences:

Key Points: 
  • SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences:
    March 15, 34th Annual Roth Conference, CFO Paolo Tombesi is scheduled to participate in one-on-one meetings.
  • AboutTurning Point Therapeutics Inc.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update

Retrieved on: 
Monday, March 7, 2022
EML4-ALK positive lung cancer, SRC, Patient, MET, ALK, ROS1, SAN, Therapy, Large-cell lung carcinoma, Cancer, TRK, GLOBE, NASDAQ, Pharmaceutical industry, CSF1R

AboutTurning Point Therapeutics Inc.

Key Points: 
  • AboutTurning Point Therapeutics Inc.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, March 3, 2022
Diagnosis, Ageing, Patient, Caregiver burden, Lists of diseases, American Academy, Microglia, Prevalence, Genetics, Neurodegeneration, Doctor of Philosophy, Life expectancy, Physical, Disease, Autosome, ALSP, Survival analysis, Mutation, AAN, Dementia, TREM2, Nasdaq, Genetic testing, Brain, GLOBE, Pharmaceutical industry, Vaccine, Medical imaging, CSF1R, MD

Our presentations at this years AAN Annual Meeting highlight the lack of major genotype-phenotype correlations and the rapidly progressive nature of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) through a survival analysis.

Key Points: 
  • Our presentations at this years AAN Annual Meeting highlight the lack of major genotype-phenotype correlations and the rapidly progressive nature of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) through a survival analysis.
  • We hope these presentations help to improve the overall understanding of ALSP, our lead indication for VGL101, our investigational fully human monoclonal antibody TREM2 agonist, said Spyros Papapetropoulos, MD, PhD, Chief Medical Officer of Vigil Neuroscience.
  • Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, inherited, autosomal dominant neurological disease with high penetrance.
  • There are currently no approved therapies for the treatment of ALSP, underlining the high unmet need in this rare indication.

AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Retrieved on: 
Wednesday, March 2, 2022
Giant, Risk, Tenosynovial giant cell tumor, Patient, Pharmacokinetics, Infection, Knee, Quality of life, Safety, Ohio State University, Macrophage, Principal, Program, Disability, CSF1R, ORR, TGCT, The James Cancer Hospital, Magnetic resonance imaging, Pain, Health, Cell, IPF, Idiopathic pulmonary fibrosis, MD, MRI, CSF1, Incidence, RECIST, GLOBE, Neoplasm, Therapy, Pharmaceutical industry, Medical imaging, Dentistry, Amgen

Data From the Phase 2 Study Support the Potential of AMB-05X as a Best-in-Class Therapy for Treatment of TGCT​REDWOOD CITY, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics targeting the colony-stimulating factor 1 receptor (CSF1R), today announced additional positive results from the first-of-its-kind local delivery Phase 2 study of AMB-05X via intra-articular (IA) injection for the treatment of tenosynovial giant cell tumor (TGCT).​“These longer-term, 12-week data from eight patients confirm the earlier positive interim results seen after 6 weeks of treatment with AMB-05X,” said Larry Hsu, Ph.D., Chief Executive Officer of AmMax Bio. “With these Phase 2 data, we have now demonstrated proof-of-concept for the intra-articular delivery of AMB-05X in patients with TGCT. Using our novel approach, we have the potential to truly transform TCGT therapy to ensure an optimal balance of efficacy and safety. Showing best-in-class potential, we look forward to further advancing this program into registration-enabling clinical studies.”

Key Points: 
  • With these Phase 2 data, we have now demonstrated proof-of-concept for the intra-articular delivery of AMB-05X in patients with TGCT.
  • Using our novel approach, we have the potential to truly transform TCGT therapy to ensure an optimal balance of efficacy and safety.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT).
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).

Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference

Retrieved on: 
Tuesday, March 1, 2022
EML4-ALK positive lung cancer, SRC, Patient, Investor, MET, ALK, ROS1, SAN, Therapy, Large-cell lung carcinoma, Webcast, Cancer, Conference, TRK, GLOBE, NASDAQ, Pharmaceutical industry, CSF1R

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference.

Key Points: 
  • SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference.
  • Dr. Countouriotis session is scheduled to take place on Tuesday, March 8 from 11:10 a.m. to 11:40 a.m.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

AKESO ANNOUNCED COLLABORATION WITH CHIPSCREEN BIOSCIENCES TO INITIATED A CLINICAL TRIAL OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY IN COMBINATION WITH CHIAURANIB FOR PD-(L)1 PRETREATED ES-SCLC

Retrieved on: 
Wednesday, March 2, 2022
Aurora, Stomach, Kidney cancer, Toxicity, Patient, Cervical cancer, Research, CDE, Industry, Phase, Liver cancer, Squamous cell carcinoma, Food, VEGFR, Safety, PD-1, Food and Drug Administration, Shanghai Stock Exchange, National Medical Products Administration, Company, CMC, Nasopharyngeal carcinoma, Mitosis, GMP, Inflammation, Neoplasm, Cancer, Clinical trial, Degenerative disease, Ovarian cancer, Review, Partnership, Lung cancer, III, AK104, Drug discovery, Single-chain variable fragment, Pharmaceutical industry, Fine chemical, Chidamide, Bevacizumab, CSF1R

ABOUT CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104)

Key Points: 
  • ABOUT CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104)
    Cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104) is a novel, first-in-class PD-1/ CTLA-4 bi-specific immuno-oncology backbone drug independently developed by the Company.
  • Its main indications include lung cancer, liver cancer, gastric cancer, cervical cancer, kidney cancer, esophageal squamous cell cancer, nasopharyngeal carcinoma and other malignant tumors.
  • As a result, Cadonilimab is expected to become the world's first PD-1-based bi-specific antibody approved for launch.
  • Chiauranib is a novel chemical structure independently designed and developed by Chipscreen Biosciences with global patent protection.

Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates

Retrieved on: 
Monday, February 28, 2022
Annual report, COVID-19, Therapy, SRC, IND, KRAS, Form 10-K, Private Securities Litigation Reform Act, Research, DOR, Pharmacokinetics, Investment, Chinese Center for Disease Control and Prevention, Security, Safety, NMPA, SAN, National Medical Products Administration, CEO, NSCLC, D, Population, NASDAQ, CDE, Hand, EML4-ALK positive lung cancer, TRK, G&A, Cancer, ROS1, ORR, BID, Patient, GLOBE, Turning Point, EGFR, Investigational New Drug, Second Half, ALK, TKI, FDA, U.S. Securities and Exchange Commission, Large-cell lung carcinoma, MET, SEC, Pharmaceutical industry, Lithium, CSF1R

Updated durability data from ROS1-positive TKI-nave NSCLC patients in the Phase 1 portion of the TRIDENT-1 trial continues to demonstrate best-in-class potential.

Key Points: 
  • Updated durability data from ROS1-positive TKI-nave NSCLC patients in the Phase 1 portion of the TRIDENT-1 trial continues to demonstrate best-in-class potential.
  • Turning Point projects its cash position is sufficient to fund current operations into the second half of 2024.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

Retrieved on: 
Tuesday, March 1, 2022
Janus, Hematology, TYK2, Pneumonia, JAK3, Mount Sinai, Population, HIV disease progression rates, Heart, Webcast, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Peripheral edema, BAT, Bleeding, Toxicity, Fever, Haematopoiesis, Diarrhea, Associate professor, ID, CTI, JAK1, Cytokine, CTIC, Nausea, FMS, Vera, Disease, BD, CD135, DRI, Food, CSF1R, Acquisition, FLT3, Ruxolitinib, Caregiver, Cytopenia, Skin, FDA, Primary myelofibrosis, Platelet, Nasdaq, BID, Thrombocytopenia, Patient, Anemia, Pacritinib, Icahn School of Medicine at Mount Sinai, Oncology, JAK2, Pharmaceutical industry, Medicine

The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).

Key Points: 
  • The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).
  • As part of the accelerated approval, CTI is required to describe a clinical benefit in a confirmatory trial.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

AmMax Bio Announces the Appointment of Biotechnology Executive, Michael Kavanaugh, M.D., as Independent Board Member

Retrieved on: 
Thursday, February 24, 2022
Giant, GLOBE, Risk, Therapy, Board of directors, Tenosynovial giant cell tumor, Cell, Board, CSF1, Pain, IPF, Disability, University, Novartis, Industry, University of California, San Francisco, Drug development, TGCT, Signal transduction, Coronavirus Scientific Advisory Board (Turkey), CSF1R, Biotechnology, Independent Board for Presbyterian Foreign Missions, Patient, Quality of life, Macrophage, Idiopathic pulmonary fibrosis, Program, Incidence, Infection, Health, Pharmaceutical industry, Chiron, Amgen, Medicine

We are very pleased to welcome Dr. Kavanaugh to our Board of Directors, said Larry Hsu, Ph.D., Chairman of the Board and Chief Executive Officer of AmMax Bio.

Key Points: 
  • We are very pleased to welcome Dr. Kavanaugh to our Board of Directors, said Larry Hsu, Ph.D., Chairman of the Board and Chief Executive Officer of AmMax Bio.
  • We welcome Michael to our Board and look forward to benefiting from his future contributions.
  • "I am very happy to join the Board of AmMax Bio, said Michael Kavanaugh, M.D.
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 2, 2022
Webcast, Large-cell lung carcinoma, Private Securities Litigation Reform Act, Patient, Therapy, SAN, NASDAQ, Investor, SEC, EML4-ALK positive lung cancer, COVID-19, Cancer, SRC, Turning Point, Form 10-Q, ROS1, GLOBE, ALK, MET, Conference, TRK, U.S. Securities and Exchange Commission, Pharmaceutical industry, CSF1R

Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

Key Points: 
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics business and the other risks described in Turning Point Therapeutics filings with theSecurities and Exchange Commission (SEC), including its quarterly report on Form 10-Q filed with theSEConNovember 9, 2021.